ALS

May 21, 2010
1 Comment

Dormant Blog

I haven’t updated my blog for quite sometime now.  But fear not, I’m back and will be updating my blog regularly.  I needed sometime to adjust to the technological changes that I need to keep up with my illness.

Read the full article →
April 16, 2010
0 Comments

Knopp Neurosciences Presents Further Encouraging Trends in Its Phase 2 Study of KNS-760704 (Dexpramipexole) in ALS

This is really encouraging, there is going to be a new drug In the market soon. Finally an alternative to very expensive Rilutek, I’m so excited… In Part 2 of the study, 92 subjects were re-randomized to receive daily doses of 50 mg or 300 mg of dexpramipexole for 24 weeks. In addition to results [...]

Read the full article →
March 23, 2010
0 Comments

Another Stem Cell Trial To Begin

This is awesome news! In the first federal-government-approved clinical trial of its kind in the U.S., patients with amyotrophic lateral sclerosis (ALS) will be treated with their own stem cells. The aim is to hopefully slow the progress of the fatal, neurodegenerative disease. TCA Cellular Therapy of Covington, a privately held stem-cell research and development [...]

Read the full article →
March 10, 2010
1 Comment

Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis

A new potential treatment on the horizon. I’m so excited! Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s Disease. CK-2017357 is [...]

Read the full article →
March 8, 2010
0 Comments

ALS SOD1 Trial: A ‘Watershed Moment’ | Quest Magazine Online

  Isis Pharmaceuticals of Carlsbad, Calif., has begun a phase 1 clinical trial of its experimental compound ISIS-SOD1-Rx in people with familial (inherited) ALS caused by toxic SOD1 protein molecules. “This is a watershed moment,” said R. Rodney Howell, a metabolic disease specialist and chairman of the MDA Board of Directors. “More than 30 people [...]

Read the full article →

← Previous Entries

Next Entries →